YMTX vs. ELDN, ORGS, VTGN, CKPT, PTN, MNPR, SGTX, MEIP, LPTX, and UNCY
Should you be buying Yumanity Therapeutics stock or one of its competitors? The main competitors of Yumanity Therapeutics include Eledon Pharmaceuticals (ELDN), Orgenesis (ORGS), VistaGen Therapeutics (VTGN), Checkpoint Therapeutics (CKPT), Palatin Technologies (PTN), Monopar Therapeutics (MNPR), Sigilon Therapeutics (SGTX), MEI Pharma (MEIP), Leap Therapeutics (LPTX), and Unicycive Therapeutics (UNCY). These companies are all part of the "pharmaceutical preparations" industry.
Yumanity Therapeutics vs.
Yumanity Therapeutics (NASDAQ:YMTX) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, community ranking, dividends, institutional ownership, risk and earnings.
Eledon Pharmaceuticals received 4 more outperform votes than Yumanity Therapeutics when rated by MarketBeat users. However, 70.00% of users gave Yumanity Therapeutics an outperform vote while only 64.29% of users gave Eledon Pharmaceuticals an outperform vote.
Eledon Pharmaceuticals has a net margin of 0.00% compared to Yumanity Therapeutics' net margin of -660.61%. Eledon Pharmaceuticals' return on equity of -25.14% beat Yumanity Therapeutics' return on equity.
Yumanity Therapeutics has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500.
Eledon Pharmaceuticals has a consensus target price of $22.00, suggesting a potential upside of 746.15%. Given Eledon Pharmaceuticals' higher probable upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than Yumanity Therapeutics.
Eledon Pharmaceuticals has lower revenue, but higher earnings than Yumanity Therapeutics. Yumanity Therapeutics is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Eledon Pharmaceuticals had 3 more articles in the media than Yumanity Therapeutics. MarketBeat recorded 3 mentions for Eledon Pharmaceuticals and 0 mentions for Yumanity Therapeutics. Eledon Pharmaceuticals' average media sentiment score of 0.22 beat Yumanity Therapeutics' score of 0.00 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.
25.1% of Yumanity Therapeutics shares are held by institutional investors. Comparatively, 45.6% of Eledon Pharmaceuticals shares are held by institutional investors. 12.5% of Yumanity Therapeutics shares are held by insiders. Comparatively, 13.8% of Eledon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Eledon Pharmaceuticals beats Yumanity Therapeutics on 14 of the 16 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding YMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Yumanity Therapeutics Competitors List